Date:2/1/2012

p Chairman, Global Pharmaceuticals for Johnson & Johnson where he was responsible for leading and developing the strategic growth agenda, including the strategy for licensing, acquisitions and divestments, and ensuring alignment with global strategic functions, research and development and the commercial organizations.  Prior to that, Mr. Norton served as Johnson & Johnson's Company Group Chairman, Worldwide Commercial and Operations for the CNS, Internal Medicine and Virology franchise and had held the position of Company Group Chairman for Johnson & Johnson's pharmaceutical businesses in Europe, the Middle East, and Africa, as well as for North America and Canada.  During his thirty-two year career at Johnson & Johnson, Mr. Norton held a wide range of management positions of increasing responsibility in Europe, Australia, New Zealand and the United States.  He began his career there as a product manager for Janssen Pharmaceutica in Australia and advanced to international product manager at Janssen's Belgium headquarters where he later served as managing director of Janssen Australia and New Zealand.  Mr. Norton is currently Chairman of the Board of Directors of the American Foundation for Suicide Prevention.  He previously served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and was a Board member of the Alliance for Aging Research.Conference Call and Webcast
The Company will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on February 1, 2012 to discuss this announcement and to answer questions.  To participate by telephone, please dial:

Domestic:
(877) 278-8171
International:
(574) 941-7303
Conference ID:
48497482

The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to
'/>"/>

SOURCE Savient Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results